Tango Therapeutics, Inc. (TNGX): R&D Expense
$132.16M
Year ended 2025-12-31
$133.65M
Trailing 12 months to 2026-06-30
+7.7%
3-year compound annual growth
+21.5%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $132.16M | -8.2% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $143.92M | +24.9% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $115.20M | +8.8% | 2026-03-05, From 2023-01-01 |
| 2022-12-31 | $105.91M | +36.4% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $77.64M | +55.3% | 2023-03-27, From 2021-01-01 |
| 2020-12-31 | $49.99M | n/a | 2022-03-28, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $132.16M | -8.2% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $115.11M | +16.1% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $11.90M | -79.0% |
| Journey Medical Corp (DERM) | 2025-12-31 | $480.0K | -95.1% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $106.74M | -18.8% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $38.47M | -60.2% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $251.07M | +47.7% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $0 | -100.0% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $0 | -100.0% |
Compare TNGX, NUVB, FBIO, DERM side by side · Screen every company in Pharmaceutical Preparations ↗